DermTech Inc. to Pay Up to $5M to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer Tests
A skin cancer testing company formerly known as DermTech, Inc. has agreed to settle allegations that it violated the False Claims Act by knowingly submitting false claims for unreliable skin cancer tests to the Medicare program. DermTech is now liquidating as DTech Liquidating Inc. after filing for Chapter 11 bankruptcy in the District of Delaware in June 2024. As part of the resolution announced today, the...
What happened
A skin cancer testing company formerly known as DermTech, Inc. has agreed to settle allegations that it violated the False Claims Act by knowingly submitting false claims for unreliable skin cancer tests to the Medicare program. DermTech is now liquidating as DTech Liquidating Inc. after filing for Chapter 11 bankruptcy in the District of Delaware in June 2024. As part of the resolution announced today, the...
Why it matters
The development may change operating conditions or market expectations around Regulation. Further confirmation and measurable outcomes matter.
Affected entities
View evidence
2 reports · 1 original report · 1 independent
- U.S. Department of JusticePrimary source · Supports · EN · 100%DermTech Inc. to Pay Up to $5M to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer Tests ↗
- U.S. Department of JusticePrimary source · Supports · EN · 80%DermTech Inc. to Pay Up to $5M to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer Tests ↗
Claims
- DermTech Inc. to Pay Up to $5M to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer Tests Observed
Conflicts
No material conflict detected in the available evidence.
Timeline
- First reported
Market move following event
Market reaction is not yet available for this asset and time window.